Wuhan Hiteck Biological Pharma Co Ltd (300683) - Total Assets
Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) holds total assets worth CN¥2.64 Billion CNY (≈ $385.87 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Wuhan Hiteck Biological Pharma Co Ltd for net asset value and shareholders' equity analysis.
Wuhan Hiteck Biological Pharma Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's total assets have evolved over time, based on quarterly financial data.
Wuhan Hiteck Biological Pharma Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wuhan Hiteck Biological Pharma Co Ltd's total assets of CN¥2.64 Billion consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.3% |
| Accounts Receivable | CN¥307.61 Million | 10.5% |
| Inventory | CN¥108.98 Million | 3.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥279.24 Million | 9.5% |
| Goodwill | CN¥263.59 Million | 9.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300683 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Hiteck Biological Pharma Co Ltd's current assets represent 44.5% of total assets in 2024, a decrease from 82.5% in 2013.
- Cash Position: Cash and equivalents constituted 14.3% of total assets in 2024, down from 39.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 4.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 10.5% of total assets.
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Total Assets
Key competitors of Wuhan Hiteck Biological Pharma Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Wuhan Hiteck Biological Pharma Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.60 | 4.03 | 3.62 |
| Quick Ratio | 4.25 | 3.66 | 3.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥883.24 Million | CN¥993.17 Million | CN¥960.99 Million |
Wuhan Hiteck Biological Pharma Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wuhan Hiteck Biological Pharma Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | CN¥2.94 Billion |
| Market Capitalization | $676.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Hiteck Biological Pharma Co Ltd's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Wuhan Hiteck Biological Pharma Co Ltd's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below shows the annual total assets of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.94 Billion ≈ $429.72 Million |
-1.17% |
| 2023-12-31 | CN¥2.97 Billion ≈ $434.79 Million |
+9.79% |
| 2022-12-31 | CN¥2.71 Billion ≈ $396.03 Million |
+0.33% |
| 2021-12-31 | CN¥2.70 Billion ≈ $394.73 Million |
+23.37% |
| 2020-12-31 | CN¥2.19 Billion ≈ $319.96 Million |
+0.79% |
| 2019-12-31 | CN¥2.17 Billion ≈ $317.47 Million |
+0.66% |
| 2018-12-31 | CN¥2.16 Billion ≈ $315.40 Million |
+12.92% |
| 2017-12-31 | CN¥1.91 Billion ≈ $279.31 Million |
+83.67% |
| 2016-12-31 | CN¥1.04 Billion ≈ $152.07 Million |
+19.11% |
| 2015-12-31 | CN¥872.49 Million ≈ $127.67 Million |
+8.88% |
| 2014-12-31 | CN¥801.37 Million ≈ $117.27 Million |
+81.69% |
| 2013-12-31 | CN¥441.07 Million ≈ $64.54 Million |
-- |
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more